חזרה לתוצאות החיפוש

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

ישראלמגייס משתתפיםPHASE1, PHASE2

מצבים רפואיים

Breast Neoplasms · Breast Cancer

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • Rambam Health Care Campus ( Site 0011), Haifa, Israel

    Study coordinator · 04-7776234

  • Rabin Medical Center ( Site 0012), Petah Tikva, Israel

    Study coordinator · +972-505533121

  • Sheba Medical Center ( Site 0010), Ramat Gan, Israel

    Study coordinator · 03-5304498

  • University of Colorado Anschutz Medical Campus ( Site 0057), Aurora, Colorado, United States

    Study coordinator · 720-848-1030

  • Dana-Farber Cancer Institute ( Site 0050), Boston, Massachusetts, United States

    Study coordinator · 877-338-7425

  • Rutgers Cancer Institute of New Jersey ( Site 0052), New Brunswick, New Jersey, United States

    Study coordinator · 732-235-2465

  • Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053), Greenville, South Carolina, United States

    Study coordinator · 864-455-3600

  • Inova Schar Cancer Institute ( Site 0051), Fairfax, Virginia, United States

    Study coordinator · 571-472-4724

  • Kingston General Hospital ( Site 0061), Kingston, Ontario, Canada

    Study coordinator · 6135336541

  • Princess Margaret Cancer Centre ( Site 0001), Toronto, Ontario, Canada

    Study coordinator · 416-946-4501

  • Centre Hospitalier de l'Université de Montréal ( Site 0004), Montreal, Quebec, Canada

    Study coordinator · (514)890-8000 x20737

  • Jewish General Hospital ( Site 0003), Montreal, Quebec, Canada

    Study coordinator · 514-340-8222

  • Nagoya City University Hospital ( Site 0020), Nagoya, Aichi-ken, Japan

    Study coordinator · +81-52-851-5511

  • Seoul National University Hospital ( Site 0030), Seoul, South Korea

    Study coordinator · 82-2-2072-0850

  • Asan Medical Center ( Site 0031), Seoul, South Korea

    Study coordinator · +82-2-1688-7575

  • University College London Hospital ( Site 0041), London, Camden, United Kingdom

    Study coordinator · +442034472930

  • The Beatson West of Scotland Cancer Centre ( Site 0043), Glasgow, Glasgow City, United Kingdom

    Study coordinator · +441413017000

  • St Bartholomew s Hospital ( Site 0040), London, London, City of, United Kingdom

    Study coordinator · +442073777000
מובילי המחקר

  • Medical Director

    Study Director

    Merck Sharp & Dohme LLC

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)